Wegovy Pill in Australia: How to Check Its TGA Approval Status

Yes—the TGA’s public Australian Register of Therapeutic Goods (ARTG) now lists a Wegovy tablet. As checked on November 4, 2026, the register includes “WEGOVY semaglutide 25 mg tablet blister pack,” ARTG ID 522759, with an ARTG date of November 3, 2026. The entry names Novo Nordisk Pharmaceuticals Pty Ltd as sponsor and semaglutide as the active ingredient. You can open the TGA record for ARTG ID 522759 to confirm the live details.

This is a specific registration record for a tablet formulation. It is different from the older Wegovy injection entries. Check the product name and formulation in the ARTG rather than relying on a headline that only says “Wegovy” or “semaglutide.”

What the TGA record confirms

The ARTG is the TGA’s public reference database for therapeutic goods that can be supplied in Australia. The record confirms that a Wegovy semaglutide tablet pack is included in the register. TGA’s current public entry identifies the 25 mg tablet blister pack, ARTG ID 522759, the sponsor, and the ingredient. The page currently displays licence status “A”; check the live record if you need the status on a later date, because entries and details can change.

The entry date matters: TGA guidance explains that the ARTG start date is when a product is added to the register, while an effective date records when the latest change to the entry took effect. For this tablet record, the TGA page shows November 3, 2026. That date is not an estimate of when a pharmacy near you will receive stock.

Registration is also not personal medical advice. It does not tell you whether Wegovy is suitable for you, what dose to take, what a pharmacy will charge, or whether a particular pharmacy has it available. Ask a doctor or pharmacist about treatment and supply questions.

How to check the Wegovy pill’s TGA status

1. Start at the official ARTG search. Use the TGA’s instructions for searching the ARTG and open its search function. The TGA says you can search by product name, sponsor, active ingredient, or ARTG identifier number.
2. Search for the exact tablet entry. Search “WEGOVY semaglutide 25 mg tablet blister pack” or enter ARTG ID “522759.” The direct TGA entry page is the clearest match for the tablet record checked for this guide.
3. Check the formulation and sponsor. Make sure the result says “tablet” and names Novo Nordisk Pharmaceuticals Pty Ltd as sponsor. If a result says solution for injection, it is a different formulation. A matching active ingredient alone is not enough to show that the tablet itself has the same Australian registration.
4. Review the date and current status fields. Confirm the ARTG ID and ARTG date, then read the status displayed on the current TGA page. Do not treat an old screenshot, search result snippet, or copied number as proof that an entry remains current. The TGA says ARTG records can be changed or cancelled, so use the live page.
5. Open the public summary if you need more detail. The ARTG entry links to a public summary. Check that the product name and dosage form match the medicine you are trying to verify. The ARTG is a register of product and classification details; the TGA says it is not intended as guidance or a recommendation about whether a medicine is right for you.

Can you check the package label too?

Yes. TGA guidance says medicines included in the ARTG carry an AUST number on the label, such as an AUST R number for a registered medicine. The number identifies the product on the register. If a package is offered to you, compare its AUST number and exact product name with the ARTG entry rather than checking only the brand name.

Be cautious if an online seller shows a foreign package or claims that approval in another country proves Australian approval. A product’s country-specific authorization does not replace the Australian record. If you are unsure whether a pack is the Australian product, ask a pharmacist to check the label and ARTG details.

Why Wegovy search results can be confusing

The TGA has separate records for different formulations and regulatory changes under the same brand. For example, a TGA page for Wegovy injection records an earlier registration, and another Wegovy entry covers a later indication. Those records do not, by themselves, verify a tablet. Look for the explicit “tablet” wording in the product name.

Rybelsus is another semaglutide brand that appears in Australian records, but it is a separate tablet medicine with its own ARTG registration and approved use. The TGA’s Rybelsus page identifies that product separately. Similar ingredients do not make two brands, formulations, or indications interchangeable.

Does TGA registration mean the pill is available now?

The ARTG confirms regulatory inclusion for supply; it is not a live pharmacy inventory or retail price list. Registration and commercial availability are related but different questions. To find out whether the medicine has reached pharmacies, ask a pharmacist or contact the Australian sponsor. To check whether a medicine is subsidized, search the current Pharmaceutical Benefits Scheme schedule separately.

Wegovy is a prescription medicine. The TGA explains that prescription medicines are registered on the ARTG and assessed for quality, safety, and efficacy before approval, and that access requires a prescription from an authorized health professional. Do not use the ARTG entry to self-diagnose, select a dose, or substitute the tablet for an injectable medicine.

Quick verification checklist

• Product name includes “WEGOVY semaglutide 25 mg tablet blister pack.”
• ARTG ID is 522759.
• Sponsor is Novo Nordisk Pharmaceuticals Pty Ltd.
• The record is on the live TGA website and its status has not changed.
• The label’s AUST number, if checking a physical pack, matches the relevant ARTG product.

For this question, the key distinction is simple: the current TGA register contains a specific Wegovy tablet entry, not just an older record for an injection. Use the ARTG ID and tablet wording to verify the product, then ask a qualified health professional about suitability and a pharmacist about local availability.